Peter O'Donnell
University of Chicago
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter O'Donnell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03729180 · The ImPreSS Trial: Pharmacogenomic Decision Making at Time of SurgeryUniversity of Chicago · recruiting · Surgery · principal investigator
- N/ANCT03225820 · Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority DisparitiesUniversity of Chicago · recruiting · Information Seeking Behavior · principal investigator
- Ph2NCT02122172 · Afatinib in Advanced Refractory Urothelial CancerUniversity of Chicago · terminated · Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical TherapeuticsT32GM007019 · NIGMS · UNIVERSITY OF CHICAGO · fiscal years 2020 to 2026 · $446,666 awarded in 2026Same name and institution; not confirmed by an ID
- Pharmacogenomics to Catalyze Decision Support in Oncology CareR01HG012273 · NHGRI · UNIVERSITY OF CHICAGO · fiscal years 2023 to 2026 · $867,879 awarded in 2026Same name and institution; not confirmed by an ID
- UG1 - NCTN (Network Lead)UG1CA233327 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2026 · $701,399 awarded in 2026Same name and institution; not confirmed by an ID
- Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01R01HG009938 · NHGRI · UNIVERSITY OF CHICAGO · fiscal years 2018 to 2022 · $809,925 awarded in 2022Grant number is on one of their registry trials
- The 1200 Patients Project: Studying Clinical Implementation of PharmacogenomicsK23GM100288 · NIGMS · UNIVERSITY OF CHICAGO · fiscal years 2013 to 2016 · $185,693 awarded in 2016Same name and institution; not confirmed by an ID
- Population-Specific Genetic Determinants of Susceptibility to ChemotherapiesF32CA136123 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2009 · $32,522 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translationU54MD010723 · NIMHD · NORTHWESTERN UNIVERSITY · PI DAVID O MELTZER, Minoli A Perera · fiscal years 2016 to 2020Named on NCT03225820
- Core B: Program Development (Pilot) CoreP30AG066619 · NIA · UNIVERSITY OF CHICAGO · PI EMILY J ROGALSKI · fiscal years 2020 to 2026Named on NCT03225820
- Immunology and CancerP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI THOMAS F GAJEWSKI · fiscal years 2013 to 2026Named on NCT02122172
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:00 UTC. The ranking covers the 200 most relevant of 85 PubMed records, and a shared surname and initials can bring in a namesake. All 85 on PubMed
- 2,988 citationsRCR 94.8
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biol Blood Marrow Transplant · 20081,643 citationsRCR 39.2
- 1,070 citationsRCR 34.1
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol · 2017726 citationsRCR 22.6
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.J Clin Oncol · 2016675 citationsRCR 20.7
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.J Clin Oncol · 2019549 citationsRCR 20.8
- 460 citationsRCR 12.9
- Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.Biol Blood Marrow Transplant · 2002406 citationsRCR 8.5
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2021381 citationsRCR 18.5
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.Lancet Oncol · 2017282 citationsRCR 8.4